Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)

被引：0

作者：

Wang, Jianxiang ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,10
,11
,12
,13
]}

Huang, Xiaojun

Hu, Jianda

Li, Jianyong

Jin, Jie

Meng, Fanyi

Shen, Zhixiang

Liu, Ting

Wu, Depei

Wang, Jianmin

机构：

[1] Chinese Acad Med Sci, Inst Hematol, Beijing, Peoples R China

[2] Chinese Acad Med Sci, Blood Dis Hosp, Beijing, Peoples R China

[3] Peking Univ, Inst Hematol, Beijing, Peoples R China

[4] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[5] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China

[6] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China

[7] Jiangsu Prov Hosp, Suzhou, Peoples R China

[8] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[9] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[10] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai, Peoples R China

[11] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[12] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China

[13] Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China

来源：

关键词：

CML; dasatinib; imatinib-resistance;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / +

页数：3